Boston biopharma making antibiotics for the infections that shrug off everything else - including one drug stockpiled in case of anthrax.
Somewhere in a U.S. government warehouse, sealed treatment courses of a Paratek antibiotic sit waiting for a day nobody wants to arrive. They are insurance against anthrax - a weaponizable bacterium with a three-day clock. The same molecule, NUZYRA, is also prescribed on an ordinary Tuesday to someone with pneumonia who simply wants to breathe. One drug, two lives: the quiet emergency and the loud one. That double identity is the most honest portrait of who Paratek is right now.
Paratek Pharmaceuticals does the work that the pharmaceutical industry, by its own admission, finds commercially miserable: it makes new antibiotics. Antibiotics are taken for ten days and then, ideally, never again. They are held in reserve to protect their usefulness, which means the better the drug, the less it gets sold. It is a business model that would make any spreadsheet weep. Several of Paratek's peers tried it and went bankrupt. Paratek is still standing.
The reason is partly chemistry and partly stubbornness. The company was built on tetracycline - a venerable antibiotic class first found in soil bacteria - and the conviction that an old chemistry, re-engineered, could outflank the newest superbugs.
"To create positive stories for patients, physicians and caregivers based on trust and integrity."
Paratek was founded in 1996 by two scientists who understood the enemy better than most. Stuart B. Levy spent his career studying how bacteria evade drugs - he discovered the efflux pump mechanism of tetracycline resistance and was among the first to document resistant bacteria jumping from farm animals to farm workers, long before antibiotic resistance became a public-health headline. He died in 2019, but his fingerprints are on the company's lead drugs.
His co-founder, Walter Gilbert, won the 1980 Nobel Prize in Chemistry for inventing methods to sequence DNA. A Nobel laureate helping launch an antibiotics startup is the kind of detail that tells you the science was serious from day one.
Today the company is led by chairman Michael F. Bigham, with a leadership team that steered NUZYRA from molecule to FDA approval to the national stockpile. The team of roughly 270 works between Boston and Pennsylvania, small by pharma standards but punching well above its weight.
The founding bet was simple and contrarian: resistance is inevitable, so build drugs designed to work even after bacteria have learned their usual tricks. That bet became NUZYRA.
Paratek's catalog is small and deliberate - each product solves a specific, hard problem rather than chasing a crowded market.
Omadacycline. A once-daily, broad-spectrum modernized tetracycline available as both a pill and an IV - approved by the FDA in 2018 for community-acquired bacterial pneumonia and acute skin infections. Also developed under BARDA as a pulmonary anthrax countermeasure.
Sarecycline. A narrow-spectrum tetracycline derivative discovered by Paratek and developed for moderate-to-severe acne vulgaris - proof the company's chemistry reaches beyond hospital wards.
An exhalation-delivery nasal spray in Paratek's commercial portfolio for chronic rhinosinusitis and nasal polyps, broadening the company past pure anti-infectives.
In a pilot pulmonary anthrax efficacy study, the result was about as stark as data gets. The bars below tell it plainly.
Paratek earns money three ways. It sells NUZYRA and its portfolio to hospitals and physicians. It collects royalties from partners who carry its drugs into other markets - Zai Lab in China for omadacycline, Almirall in the U.S. for SEYSARA. And it draws on government biodefense funding, where BARDA's Project BioShield pays Paratek to develop and stockpile NUZYRA against biological threats.
That third leg is the clever part. Antibiotics rarely pay for themselves through sales alone. By making NUZYRA a national-security asset as well as a clinical one, Paratek found a customer - the U.S. government - whose interest in the drug does not depend on how often it is prescribed.
In 2024 the company completed a U.S. onshoring program, making NUZYRA the only novel antibiotic with fully domestic supply and manufacturing - useful when your buyer is a government that worries about supply chains.
Double duty. NUZYRA is both an everyday pneumonia drug and a stockpiled biodefense countermeasure. Few medicines hold both jobs.
Nobel pedigree. Co-founder Walter Gilbert won the 1980 Nobel Prize in Chemistry before helping start an antibiotics company.
Ahead of the curve. Co-founder Stuart Levy warned about resistant bacteria spreading from livestock decades before it was front-page news.
Hard mode. Antibiotics are notoriously unprofitable; several rivals went bankrupt. Paratek leaned on biodefense funding to survive.
Made in America. By 2024, NUZYRA's entire supply chain was onshored to the U.S. - a rarity for any modern drug.
Old chemistry, new tricks. Tetracyclines date to the 1940s; Paratek re-engineered them to beat resistance built up over 80 years.
Curated searches for talks, interviews, and product explainers - antibiotic resistance is a topic that rewards listening.
Return to those sealed courses waiting in storage. Most of them will expire unused, and that is the point - their value is measured in disasters that never happen and pneumonia patients who quietly recover. Paratek built a company around a paradox: the better its drugs work, the less anyone should need them. In a world racing toward antibiotic resistance, that is not a flaw in the plan. It is the plan. The warehouse stays stocked, the bacteria keep adapting, and Paratek keeps showing up for a fight most companies decided wasn't worth having.